(Alliance News) - Syncona Ltd on Thursday reported a negative net asset value total return for the financial year to date, despite NAV rising during its third quarter. Read More
(Alliance News) - Syncona Ltd on Wednesday said portfolio company Achilles Therapeutics PLC is planning to return capital to shareholders though a members' solvent voluntary liquidation. Read More
(Alliance News) - Stock prices in London were mostly lower at midday on Friday as market participants continue digesting US jobless data and unrest in Mozambique puts miners on edge. Read More
(Alliance News) - Syncona Ltd on Friday said one of its investments Achilles Therapeutics PLC has sold its technology assets to AstraZeneca PLC for USD12 million. Read More
(Alliance News) - The FTSE 100 index in London was called slightly lower on Friday, as investors digest holiday-season sales results in the US and UK. Read More
(Alliance News) - Syncona Ltd on Friday reported promising trial results for the drug laru-zova, the lead asset of Syncona subsidiary Beacon Therapeutics Holdings Ltd. Read More
(Alliance News) - Syncona Ltd on Thursday said it launched a new portfolio company as it reported a fall in net asset value, citing a weaker US dollar. Read More
(Alliance News) - Syncona Ltd announced on Monday that the US Food & Drug Administration has granted marketing approval to one of its portfolio companies for a new product. Read More
(Alliance News) - Syncona Ltd on Wednesday noted positive trial results for a portfolio company's gene therapy aimed at treating people with Gaucher's disease. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Syncona Ltd on Wednesday announced it has committed GBP19.9 million in a series B financing of Purespring Therapeutics, which will be used to advance kidney treatments. Read More
(Alliance News) - Syncona Ltd on Thursday said it has committed GBP63.5 million in a series B financing of Resolution Therapeutics, which will be put towards clinical development of a liver disease treatment. Read More
(Alliance News) - Syncona Ltd on Friday said that its portfolio company, Beacon Therapeutics Holdings Ltd, has presented data at a conference in Barcelona. Read More
(Alliance News) - Syncona Ltd on Thursday announced that Achilles Therapeutics will discontinue its lead TIL-based cNeT program, close its Phase I/IIa CHIRON and THETIS clinical trials and explore strategies for maximising potential value from its remaining assets. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Syncona Ltd on Wednesday said that its portfolio company, Beacon Therapeutics, has raised USD170 million in a Series B financing. Read More